FCPM III Services B.V.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 3, 2024), FCPM III Services B.V. reported 6 stock positions worth $707.3 million. Its top holding was Newamsterdam Pharma (NAMS) at 39.6% of the portfolio, followed by Dyne Therapeutics (DYN, 31.5%) and Engene (ENGN, 20.8%). Compared with Q4 2023, it added to 1 and reduced 2. The biggest buy was Dyne Therapeutics (DYN, shares +28%) and the biggest sale Replimune (REPL, shares −0%).
- Most Recent 13F
- Q2 2026
- Location
- NAARDEN, P7
- CIK
- 0002013410
- Portfolio Value
- $707.3M (Q1 2024)
- SEC Filing
- 0001802806-24-000028 ↗ filed May 3, 2024
Holdings Value
Holdings 6 stocks · $707.3M
| NAMS Newamsterdam Pharma Co. NV | 39.56% | 11,831,461 | $279.8M | No change |
| DYN Dyne Therapeutics Inc. | 31.49% | 7,845,364 | $222.7M | Add +28.0% |
| ENGN Engene Holdings Inc. | 20.79% | 8,677,951 | $147.1M | No change |
| REPL Replimune Group Inc. | 5.62% | 4,866,449 | $39.8M | Reduce 0.0% |
| ENGENE HOLDINGS INC | 2.12% | 2,878,148 | $15.0M | Reduce -25.8% |
| ACHL Achilles Therapeutics PL-ADR | 0.42% | 2,390,050 | $3.0M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| REPL Replimune Group Inc. | Reduce 0.0% | 5.62% | −6.47 |
| ENGENE HOLDINGS INC | Reduce -25.8% | 2.12% | +1.40 |
Portfolio Buys Q4 2023 → Q1 2024
| DYN Dyne Therapeutics Inc. | Add +28.0% | 31.49% | +7.46 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 11 | $750.4M | NAMS, MPLT, DYN, VOR, DMRA |
| Q1 2026 | 10 | $722.2M | NAMS, DYN, VOR, ENGN, MPLT |
| Q4 2025 | 10 | $762.9M | NAMS, DYN, ENGN, RAPT, MPLT |
| Q3 2025 | 9 | $500.4M | NAMS, DYN, ENGN, ATXS, BCYC |
| Q2 2025 | 8 | $369.2M | NAMS, DYN, REPL, ENGN, BCYC |
| Q1 2025 | 7 | $413.7M | NAMS, DYN, ENGN, REPL, BCYC |
| Q4 2024 | 8 | $592.4M | NAMS, DYN, ENGN, BCYC, REPL |
| Q3 2024 | 7 | $582.3M | DYN, NAMS, ENGN, REPL, BCYC |
| Q2 2024 | 7 | $678.1M | DYN, NAMS, ENGN, REPL, BCYC |
| Q1 2024 | 6 | $707.3M | NAMS, DYN, ENGN, REPL, ENGENE HOLDINGS INC |